DataMeds AI Inc. (MEDS) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MEDS scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows:

• Fundamental Cash Engine: 7 / 20 (ROIC -35%; FCF yield 0%). The cash-generation pillar is weak; the company is not converting operations into free cash flow or returns on invested capital.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). The institutional-flow pillar is near the bottom of its range, indicating little supportive smart-money positioning per the rating inputs.
• Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider-conviction signals are weak per the rating.
• Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). Beta of 1.0 places the stock at market-level sensitivity, but the rating assigns limited regime-fit credit.
• Forensic Balance Sheet: 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The forensic pillar flags balance-sheet and accounting-quality concerns, with a low Piotroski F-Score.

For a prospective investor, the rating implies that upside depends on a turnaround in cash generation and sentiment, while the forensic and flow pillars currently point the other way. Valuation is difficult to anchor: forward earnings multiples are not available in the source data, and the reported losses mean conventional earnings-based comparisons cannot be drawn. The 52-week range of $0.82 to $38.5 and the current price of $2.03 show extreme price dispersion, which the rating reflects as high risk rather than as a signal in itself.

DataMeds AI Inc. (MEDS) is a NASDAQ-listed issuer in the Health Care sector and Other Pharmaceuticals industry, per the profile. Per the recent news wire, the company has licensed U.S. rights to a direct-to-consumer GLP-1 weight-management platform and offers a ChemoFx cancer test that has been added to Medicaid coverage by Humana. Revenue is reported in the SEC financials, but the source data does not break revenue down by product or customer segment beyond these items. Not available in source data for detailed monetization mix.

Per the SEC financials, gross margin is -27.5%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable forensic inputs. Debt-to-equity is 0.5 and cash is reported as $0.0M for FY 2025, so the balance-sheet posture rests on minimal liquidity against $12.6M of reported debt.

• Regained NASDAQ compliance (CATALYST, GREEN): a headline reports DataMeds regaining compliance with NASDAQ listing standards.
• Possible extra share issuance (MARKET WIRE, YELLOW): a headline indicates a consumer weight-management license could require additional shares.
• Humana Medicaid coverage for ChemoFx (MARKET WIRE, YELLOW): a headline reports the stock rising after Humana added Medicaid coverage for the cancer test.
• Share offering and selling into strength (CATALYST, GREEN): a kalkine.ca headline questions selling after a 7.43% gain and a share offering.
• GLP-1 U.S. rights licensing (MARKET WIRE, YELLOW): a headline reports licensing of U.S. rights to a direct-to-consumer GLP-1 platform.
• Revenue and oncology bets (CATALYST, GREEN): a Timothy Sykes headline attributes a surge to revenue and oncology.

Risk watch items include the possible share dilution flagged in the license-related headline and the share offering referenced by kalkine.ca. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.

• What is the terms and share count of the consumer weight-management license that could require additional shares, and how large is the potential dilution?
• What were the size and terms of the recent share offering, and how much cash did it raise relative to the reported $0.0M cash position?
• What drove the revenue increase from $18.1M to $23.3M, and how much of it is recurring versus one-time?
• What explains the jump in net loss from $-6.9M to $-101.3M in FY 2025, and are there non-recurring charges?
• What are the terms of the debt reported at $12.6M, including maturities and covenants?